Subcutaneous immunoglobulin (SCIG) is increasingly utilized in primary immunodeficiency (PI). Understanding factors associated with treatment experience and satisfaction can optimize patient outcomes. We analyzed Immune Deficiency Foundation (IDF) survey data to evaluate patient-reported outcomes (PROs) in relation to SCIG training and infusion characteristics. Respondents’ PRO scores were rank ordered into ‘best’, ‘intermediate’, and ‘worst’ tertiles. Predicted probabilities of being in the best tertile with any combination of characteristics were generated for each PRO. In 366 SCIG respondents, higher odds of being in the best PRO tertile were driven by favorable training characteristics (particularly, higher confidence post-training and no training barriers) and efficient infusions (infusion preparation ≤20 min and actual infusion < 2 h). Age (≤17 years old) and treatment experience (> 2 years) increased the odds of being in the best tertiles. Compared with the least favorable training/infusion characteristics, those with the most favorable training/infusion characteristics had higher predicted probabilities of being in the best tertiles: TSQM side effects, 59% vs 4%; convenience, 52% vs 4%; effectiveness, 27% vs 13%; global, 26% vs 3%; PROMIS Fatigue, 44% vs 18%. Increased experience with SCIG consistently improved PROs, but our findings predicted that enhanced training and infusion characteristics improve patient treatment satisfaction beyond that achieved by experience alone.

中文翻译：

---

原发性免疫缺陷中的皮下免疫球蛋白 - 训练和输注特征对患者报告结果的影响。

皮下免疫球蛋白 (SCIG) 越来越多地用于原发性免疫缺陷 (PI)。了解与治疗经验和满意度相关的因素可以优化患者的治疗效果。我们分析了免疫缺陷基金会 (IDF) 调查数据，以评估与 SCIG 训练和输注特征相关的患者报告结果 (PRO)。受访者的 PRO 分数按“最佳”、“中等”和“最差”三分位数排序。为每个 PRO 生成具有任意特征组合的最佳三分位数的预测概率。在 366 名 SCIG 受访者中，良好的训练特征（特别是训练后信心更高且无训练障碍）和有效输注（输注准备≤20 分钟，实际输注 < 2 小时）推动了获得最佳 PRO 三分位数的更高几率。年龄（≤17 岁）和治疗经验（> 2 年）增加了处于最佳三分位数的几率。与最不利的训练/输注特征相比，那些具有最有利训练/输注特征的人在最佳三分位数中的预测概率更高：TSQM 副作用，59% vs 4%；便利性，52% vs 4%；有效性，27% vs 13%；全球，26% 对 3%；PROMIS 疲劳，44% 对 18%。增加使用 SCIG 的经验持续改善 PRO，但我们的研究结果预测，增强的训练和输液特性可提高患者治疗满意度，超出仅凭经验所能达到的水平。那些具有最有利的训练/输注特征的人具有更高的预测概率处于最佳三分位：TSQM 副作用，59% 对 4%；便利性，52% vs 4%；有效性，27% vs 13%；全球，26% 对 3%；PROMIS 疲劳，44% 对 18%。使用 SCIG 的经验增加持续改善 PRO，但我们的研究结果预测，增强的训练和输液特性可提高患者治疗满意度，超出仅凭经验所能达到的水平。那些具有最有利的训练/输注特征的人具有更高的预测概率处于最佳三分位：TSQM 副作用，59% 对 4%；便利性，52% vs 4%；有效性，27% vs 13%；全球，26% 对 3%；PROMIS 疲劳，44% 对 18%。增加使用 SCIG 的经验持续改善 PRO，但我们的研究结果预测，增强的训练和输液特性可提高患者治疗满意度，超出仅凭经验所能达到的水平。